Jascayd (Nerandomilast) Dosing and Management
Starting Dose
The recommended starting dose of Jascayd is 18 mg twice daily, taken orally approximately 12 hours apart, with or without food. 1
Dose Modifications
- For intolerance: Reduce to 9 mg twice daily if patients cannot tolerate 18 mg twice daily 1
- With strong CYP3A inhibitors: Reduce to 9 mg twice daily 1
- With pirfenidone: Maintain 18 mg twice daily—do NOT reduce to 9 mg twice daily 1
- Maximum dose: 18 mg twice daily 1
Administration Instructions
Tablets can be swallowed whole or dispersed in water for patients with swallowing difficulties 1:
- Place tablet in ~100 mL non-carbonated room temperature water
- Stir regularly for 15-20 minutes until dispersed into small pieces
- Drink within 2 hours of mixing
- Rinse glass with another 100 mL water and drink to ensure full dose
Missed doses: Take next dose at scheduled time—do not double up 1
Monitoring Schedule
Clinical Monitoring
No routine laboratory monitoring is required per FDA labeling 1. However, based on clinical trial data, practical monitoring should include:
- Baseline assessment: Document FVC, assess gastrointestinal tolerance, review concomitant medications
- Weeks 2-4: Assess for gastrointestinal adverse effects (diarrhea, nausea) which are most common early in treatment 1, 2
- Week 12-16: Evaluate treatment tolerance and clinical response
- Every 3-6 months: Monitor pulmonary function (FVC), assess for disease progression, evaluate adverse effects
Key Monitoring Parameters
- Pulmonary function: FVC decline (primary efficacy measure) 3
- Gastrointestinal symptoms: Diarrhea and nausea are most frequent adverse effects 1, 2
- Weight: Monitor for unintended weight loss
- Respiratory events: Acute exacerbations, hospitalizations 4, 5
Management of Adverse Effects
Diarrhea (Most Common: 36.6% at 18 mg dose)
Diarrhea is the most frequent adverse effect and the leading cause of discontinuation (6% at 18 mg dose). 1, 2
Management algorithm:
- Mild diarrhea: Continue current dose, provide supportive care (hydration, dietary modifications)
- Moderate diarrhea: Consider dose reduction to 9 mg twice daily 1
- Severe or persistent diarrhea: Temporarily hold medication until resolution, then restart at 9 mg twice daily
- Recurrent severe diarrhea at 9 mg: Discontinue permanently
Nausea
- Occurs in approximately 20-30% of patients 1
- Management: Take with food, consider antiemetics, dose reduction to 9 mg twice daily if persistent
Other Adverse Effects
- Fatigue: Reported in clinical trials; typically mild 2
- Headache: Self-limited in most cases
- Upper respiratory infections: Monitor but generally do not require discontinuation
Discontinuation Rates
- Overall discontinuation due to adverse events: 12-16% across doses 1, 4, 5
- Lower than pirfenidone and nintedanib, representing improved tolerability 2
Important Drug Interactions
Strong CYP3A Inhibitors
Reduce Jascayd to 9 mg twice daily when used with:
- Ketoconazole, itraconazole, clarithromycin, ritonavir 1
Moderate/Weak CYP3A Inhibitors
No dose adjustment needed 1
Concomitant Antifibrotic Therapy
Jascayd can be used with nintedanib or pirfenidone 1, 3:
- 43.5% of FIBRONEER-ILD patients were on background nintedanib 3
- When combined with pirfenidone, maintain 18 mg twice daily (do not reduce) 1
- Efficacy maintained regardless of background antifibrotic use 6, 4
Clinical Pearls
- Diarrhea typically occurs early (first 2-4 weeks) and is usually mild to moderate 1, 2
- Dose reduction to 9 mg twice daily is effective for managing intolerance while maintaining clinical benefit 3
- Discontinuation rates are lower than other IPF therapies, making this a well-tolerated option 2
- No hepatotoxicity signal observed in clinical trials—unlike some other antifibrotic agents 4, 5
- Mortality benefit observed in progressive pulmonary fibrosis trials (HR 0.51 for both doses vs placebo) 4